3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
73
Ovarian Neoplasms
46
Lung Neoplasms
26
Breast Neoplasms
26
Fallopian Tube Neoplasms
23
Small Cell Lung Carcinoma
18
Carcinoma, Ovarian Epithelial
16
Squamous Cell Carcinoma of Head and Neck
14
Neoplasms
14
Glioblastoma
13
Triple Negative Breast Neoplasms
12
Recurrence
11
Head and Neck Neoplasms
11
Lymphoma, Large B-Cell, Diffuse
10
Endometrial Neoplasms
10
Uterine Cervical Neoplasms
9
Colorectal Neoplasms
9
Stomach Neoplasms
8
Hodgkin Disease
8
Brain Neoplasms
8
Lymphoma
7
Esophageal Neoplasms
7
Central Nervous System Neoplasms
7
Prostatic Neoplasms
6
Neoplasm Metastasis
6
Glioma
6
Esophageal Squamous Cell Carcinoma
6
Astrocytoma
6
Adenocarcinoma of Lung
6
Mesothelioma
5
Interventions
pembrolizumab
1
olaparib
1
lenvatinib
1
enzalutamide
1
belzutifan
1
Prednisone
1
Etoposide
1
Docetaxel
1
Dexamethasone
1
Carboplatin
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Metastatic Castration-Resistant Prostate Cancer
×
Carboplatin
×
Clear all
NCT02861573
2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
1,200 enrolled